Please assess the completion status of the following clinical trial:

Trial Title: Synergetic B-cell Immodulation in SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18 years,~2. American College of Rheumatology (ACR) diagnosis of SLE (1997 revised criteria, see appendix 1)~3. Severe SLE flare at screening (see also section 5.2.3.2.), defined as a situation in which 1 or more of the following criteria are met:~   * Increase in SLEDAI (SLE Disease Activity Index) with 12 or more points~  * New or worse SLE-related activity of major organs, i.e.: central nervous system (CNS-) SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia \< 60, hemolytic anemia \< 4.4mmol/L (=7.0g/dL).~4. Refractory disease, defined as persisting or progressive disease activity (SLEDAI \> 6 points) despite conventional immunosuppressive treatment and 1 or more of the following criteria:~   * failure of the initial induction treatment at six months, for which a switch to another induction therapy regime has already been carried out;~  * intolerance or contraindication for cyclophosphamide and mycophenolate mofetil (MMF);~  * exceeding a cumulative dose of 15 gram of cyclophosphamide;~  * a second relapse within two years after start of the initial induction therapy~  * a relative contraindication for high-dose oral or intravenous (iv) prednisone, such as avascular osteonecrosis, previous psychosis on corticosteroids, osteoporosis and/or severe obesity (BMI =35 kg/m2).~5. ANA seropositivity, as defined by a positive ANA-titer = 1:80, before and at screening :~   * Positive test results from 2 independent time points within the study screening period; OR~  * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of ANA (eg, ANA by HEp-2 titer, ANA by ELISA) must include the date of the test.~6. Anti-DNA seropositivity, as defined by a positive anti-dsDNA serum antibody = 30 IU/mL, before and at screening:~   * Positive test results from 2 independent time points within the study screening period.~  * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of anti-dsDNA (eg, anti-dsDNA by Farr assay or ELISA) must include the date of the test.~7. Immune-complex mediated complement usage, as defined by:~   * a low C3 serum level = 0.9 g/L; OR~  * a low C4 serum level = 95 mg/L; OR~  * a reduced activation of the classical pathway \< 75%~8. Use of effective contraception~Exclusion Criteria:~1. Active pregnancy, as proven by a positive urine beta-HCG (human chorionic gonadotropin) test or a positive serum beta-HCG~2. Significant B-cell depletion (peripheral B-cell counts \< 60x10E6)~3. Significant hypogammaglobulinemia (IgG \< 8.0 g/L)~4. Immunization with a live vaccine 1 month before screening~5. Active infection at time of screening, as follows:~   * Hospitalization for treatment of infection within previous 2 months of day 0 of the study~  * Use of parenteral (intravenous of intramuscular) antibiotics ( including anti-bacterial, anti-viral, anti-fungal or anti-parasitic agents) within previous 2 months of day 0 of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab with belimumab (Type: EXPERIMENTAL): Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).